Loading...

Alkermes plc

ALKS•NASDAQ
Healthcare
Biotechnology
$33.31
$-0.60(-1.77%)
U.S. Market opens in 49h 27m

Alkermes plc (ALKS) Stock Overview

Explore Alkermes plc’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap5.6B
P/E Ratio22.80
EPS (TTM)$1.43
ROE0.14%
Fundamental Analysis

AI Price Forecasts

1 Month$27.00
3 Months$27.57
1 Year Target$30.20

ALKS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Alkermes plc (ALKS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 53.79, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $30.20.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 22.80 and a market capitalization of 5.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-1.77%
5-Day Change
-3.51%
1-Month Change
17.29%
3-Month Change
-0.89%
6-Month Change
11.78%
Year-to-Date (YTD) Change
19.05%
1-Year Change
20.38%
3-Year Change
14.15%
5-Year Change
48.24%
All-Time (Max) Change
505.64%

Contact Information

https://www.alkermes.com
353 1 772 8000
Connaught House, Dublin, NaN, 4

Company Facts

1,800 Employees
IPO DateJul 16, 1991
CountryIE
Actively Trading

Frequently Asked Questions